Additional studies are underway to better elucidate the role of EP4 in both alterations of tissue integrity as well as its relevance in gynecologic malignancy, but this preliminary data raises interest in a possible pharmacologic role for use of EP4 inhibitors to modify a number of biologic processes in vaginal cancer. This evidence concerns the gene PTGER4 and vaginal cancer.